Merck has been granted a patent for ActRII-binding proteins, including specific antibodies that inhibit ActRII activity. These proteins are intended for diagnosing and treating various diseases, including muscle wasting, fibrotic conditions, and cancer, among others. The patent details specific CDR sequences for the antibodies. GlobalData’s report on Merck gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Merck, Human telomerase RT biomarker was a key innovation area identified from patents. Merck's grant share as of June 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Actrii-binding antibodies for treating various diseases
The granted patent US12042524B2 outlines a novel activin receptor type II (ActRII)-binding antibody characterized by specific complementarity-determining regions (CDRs). The claims detail various configurations of the antibody, including those with defined amino acid sequences for both heavy (VH) and light (VL) chains, as specified in SEQ ID NOs 165, 172, and others. The antibodies are designed to bind specifically to the activin receptor type IIB (ActRIIB) and exhibit properties such as competition with other ligands for binding, modulation of Smad phosphorylation, and high binding affinity, with a dissociation constant (KD) of =1 nM and =1 pM. The patent also encompasses various forms of the antibody, including monoclonal, recombinant, humanized, and bispecific antibodies, as well as fragments like Fab and Fv.
Additionally, the patent includes claims for nucleic acid molecules encoding the ActRII-binding antibodies, vectors containing these nucleic acids, and host cells for producing the antibodies. A method for generating the antibodies through the culture of host cells is also described. Furthermore, the patent covers pharmaceutical compositions that incorporate the ActRII-binding antibodies along with a pharmaceutically acceptable carrier, indicating potential therapeutic applications. Overall, the patent presents a comprehensive framework for the development and application of ActRII-binding antibodies in biomedical research and therapeutic contexts.
To know more about GlobalData’s detailed insights on Merck, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
